Operator
Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies First Quarter 2021 Financial Results Conference Call. As a reminder, today s conference call is being recorded.
I d now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.
Juan Sanchez
Vice President of Corporate Communications and Investor Relations
Good morning and thank you all for joining us for today s conference call. Our earnings press release provides a corporate update and details of the company s financial results for the first quarter ended March 31, 2021. This press release crossed the wire a short time ago and is available on our website at intracellulartherapies.com.
Views: Visits 6
Dr. Matthew Obinna Nwaneri is an Associate Professor at Carver College of Medicine and Medical Director, Iowa Oncology Network, medical oncologist at the University of Iowa Health Care (UIHC) Born in Ibadan, Oyo State, brought up in Lagos State and in his hometown, Umuezeala-Ehime, Ehime, in Ehime-Mbano local council of Imo State, where he lived with his grandparents after his secondary education, Dr. Matthew Obinna Nwaneri is not bashful of change. Very early in life, he learnt to work hard and expect to face new challenges. His commitment to these two key principles of life has today earned him a place in the league of leading oncologists in the world, to the pride of many Nigerians.
MCLA-145 clinical update planned for 2H21
MCLA-129 first patient dosed in phase 1/2 trial
Cecile Geuijen, Ph.D., promoted to Chief Scientific Officer
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics
® and Triclonics
®), today announced financial results for the first quarter that ended March 31, 2021, and provided a business update.
“We have made significant progress on our clinical programs this quarter and we are excited to provide a clinical data update on Zeno in an oral presentation at ASCO in June, and on MCLA-145 later this year,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “In addition we continue to validate our multispecific platforms with our recent value-generating deal with Loxo Oncology at Lilly, progress wit
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021
Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2021.
“We continue to make steady progress in advancing our robust pipeline of novel oncology candidates,” said Jacob Chacko, M.D., president and chief executive officer. “As planned, we will present preliminary safety, pharmacokinetic, and translational data, as well as early efficacy data from our ongoing Phase 1 trial of ORIC-101 in combination with nab-paclitaxel in solid tumors at the upcoming ASCO Annual Meeting. In
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
News provided by
Share this article
Share this article
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep s anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors
- Preclinical studies show that pelareorep s synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors
- Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021
- Strong financial foundation with over $50 million in cash on hand and cash runway to Q4-2022